Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Epoetin Alfa for Anemia in Platinum Chemotherapy
NCT00283465Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 1999
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 4, randomised, open-label trial of epoetin alfa in anemia (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Number of patients who receive an allogenic red blood cell transfusion. Started Nov 1999; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00283465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283465.